Alex Hastie is a PhD trained scientist who has focused on scientific advances in optical genome mapping for the past 12 years.
Alex received training during his PhD in cancer genetics, biochemistry, and biophysics at the Roswell Park Cancer Institute. He focused his research on novel technology and received a patent as coinventor for a method for detection of protein-protein interactions.
After a post-doctoral fellowship at the Max Planck Institute in Munich, Germany, he joined Bionano Genomics as a scientist, where he has been an inventor on multiple patents and coauthored over 90 peer reviewed publications. Currently, Alex serves as vice president of clinical and scientific affairs where he leads clinical trials and the company’s scientific publication portfolio.